Come up with a name for your new list and we'll add to it:
Aqumen Biopharmaceuticals raised a round of funding on , . Investors include
Mitsubishi UFJ Capital.
The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degenerat…